Zenith: Advanced Epigenetic Technology; BIO CEO Update: New York, NY February 14, 2017

Here are some of my observations:

Slide 18, regarding ZEN-3694 single-agent Phase 1 trial: "Longest patient on drug now beyond 6 months; Cohort with intermittent dosing has been initiated for recommended Phase 2 dose"

Slide 22, regarding ZEN-3694/enzalutamide combo Phase 1b trial: "Four sites, including UCSF and MSKCC, open for enrollment." My note: only UCLA, UCSF and MSKCC listed as recruiting on ClincalTrial.gov as of this morning.

Slide 31, regarding patents: Regarding patent "D4B PCT application (22981-40)", the slide indicates that US fast track was granted March 2016 and also lists "~Q1, 2017" for "Use US patent to fast track patents in other jurisdictions"